(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 December 2014 (24.12.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/205300 A2

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2014/043315

(22) International Filing Date:
20 June 2014 (20.06.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/837,776 21 June 2013 (21.06.2013) US

(71) Applicants *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-Basel (CH). **IRM LLC** [US/US]; 131 Front Street, Hamilton, HM LX (BM).

(72) Inventors; and

(71) Applicants *(for US only)*: **HELDWEIN, Kurt Alex** [US/US]; 100 Technology Square, Cambridge, Massachusetts 02139 (US). **SPLAWSKI, Igor** [PL/US]; 100 Technology Square, Cambridge, Massachusetts 02139 (US). **BROGDON, Jennifer** [US/US]; 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **GOLDSTEIN, Joshua** [US/US]; 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **DOLE, William** [US/US]; 220 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **TRAUGER, John** [US/US]; 100 Technology Square, Cambridge, Massachusetts 02139 (US). **ZHANG,**

[Continued on next page]

(54) Title: LECTIN-LIKE OXIDIZED LDL RECEPTOR1 ANTIBODIES AND METHODS OF USE

(57) Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as "LOX-1"), and pharmaceutical compositions and methods of treatment comprising the same.




FIG 1A




FIG 1B

WO 2014/205300 A2

Chonghui [CN/US]; 300 Technology Square, Cambridge, Massachusetts 02139 (US).

(74) **Common Representative**: **NOVARTIS AG**; Lichtstrasse 35, CH-Basel (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*